Senti Biosciences is working with RoosterBio to ensure a quality supply of its candidate gene-modified cell therapies for ovarian cancer and other solid tumors, with a goal of bringing them into clinical testing. These investigative therapies are based on the replacement, inactivation, or introduction of genes into cells that were cultivated or modified outside the body. The…
A Phase 3 clinical trial investigating Immunomedics‘ potential therapy sacituzumab govitecan is ending early because existing results have shown sufficient evidence that the treatment is effective in patients with triple-negative breast cancer (TNBC). The decision to stop the trial was unanimously recommended by an independent data safety monitoring committee. An application to obtain approval for…
Turning our attention away from the all-intrusive pandemic (at least from the primary topics surrounding COVID-19), it’s good to take a minute from the turmoil of the virus to engage with something positive. The continual waves of uncertainty that drive COVID-19 may leave something positive in the disease’s painful wake, particularly for people with Alzheimer’s…
Topline results show a 26% response rate in a Phase 2 clinical trial evaluating Ygalo (melflufen) in patients with triple-refractory multiple myeloma, a difficult-to-treat form of this disease, the therapy’s developer, Oncopeptides, announced. These data will support a request for accelerated approval for Ygalo to treat people with triple-refractory multiple myeloma in the U.S., the company said in a…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to MEI Pharma‘s investigational compound ME-401 for treating follicular lymphoma patients who received at least two prior therapies. A therapy candidate is put on the FDA’s fast track if it can treat serious conditions and fill an unmet clinical need, either because no treatments…
Because the COVID-19 pandemic has many people staying at home, the Alzheimer’s Foundation of America (AFA) has suggestions about activities to help patients and their families stay active and engaged. “Stimulating the brain is beneficial both for individuals living with Alzheimer’s disease and their caregivers,” Charles J. Fuschillo Jr., AFA president and CEO, said in…
The 3rd annual TRUE Love Contest of the Prostate Cancer Foundation (PCF), which features inspirational stories from patients and caregivers to raise disease awareness, has selected two winners. Chosen by actress Kristen Bell from more than 100 submitted narratives, the winners are Angie Wilfong of San Antonio, Texas, and Lucy Hayes of Gold Bar, Washington. Wilfong…
Anavex Life Sciences announced plans to continue to screen and enroll patients into its active trials for Alzheimer’s disease and Rett syndrome, in accordance to institutional rules and government guidance related to the COVID-19 pandemic. A Phase 2 study of people with dementia linked to Parkinson’s disease is fully enrolled, and the company expects to announce topline results…
After a recommendation from the U.S. Food and Drug Administration (FDA), CytoDyn is planning to ask the regulatory agency for a preliminary meeting to discuss the granting of breakthrough therapy status to leronlimab for the treatment of metastatic triple-negative breast cancer (TNBC). Breakthrough therapy designation is intended to accelerate the development, review, and approval of treatments…
Treatment with Acelarin led to one complete response and two partial responses in heavily pre-treated women with platinum-resistant ovarian cancer, early results from a Phase 2 trial show. Full analysis of the study’s first part is ongoing. However, the treatment’s developer, NuCana, has decided not to continue with a planned second part to focus on trials in other cancers. Acelarin…
